Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) filed its Monthly Return for the period ended 30 June 2026, confirming stable capital structure and full compliance with public-float requirements on the Hong Kong Stock Exchange (HKEX).

Authorised / Registered Capital • H-shares: 919.07 million authorised shares at RMB 1 par value, unchanged from the previous month. • A-shares: 2.79 billion authorised shares at RMB 1 par value, also unchanged. • Combined authorised share capital stood at 3.71 billion shares.

Issued Shares • H-shares in issue totalled 919.07 million; no treasury shares were held or cancelled during the month. • A-shares in issue totalled 2.79 billion; likewise, no treasury shares were recorded. • No share options, warrants, convertibles or other instruments were outstanding or exercised.

Public Float Status SH PHARMA confirmed that its H-share public float met the HKEX minimum threshold of 5% for PRC issuers with dual listings as of 30 June 2026.

Regulatory Compliance The company attested that all applicable listing-rule and legal requirements were observed, with no changes in share classes, rights, or documentation.

Key Takeaway June 2026 saw no movements in SH PHARMA’s share capital. The issuer maintains a 3.71 billion-share authorised base and remains fully compliant with HKEX public-float rules.